Heidelberg Health Economic Summer School

The DKFZ Division of Health Economics, Hochschule Heilbronn and University of Heidelberg offer a summer school in health economics on July 1-5, 2019, in Heidelberg, Germany. The summer school will introduce health economics concepts and address practical issues faced by health care decision makers. It also includes an advance module of an in-depth review of the strengths and limitations of the conventional approaches. For more information on the summer school, and to register for it, please refer to this website.


Next Open Seminars

April 25, 2019. 11:30 am – 1:00 pm
Dr. Valesca Retèl. (Early) Health Economics of Next Generation Sequencing in Personalized Oncology

More News

The DKFZ Division of Health Economics in HTAi Conference in Cologne (June 2019)
Panel - HTA, Social Preferences Measurement, And (Ultra) Rare Disorders: Social Cost Value Analysis for HTA
Prof. Michael Schlander and the Division of Health Economics is responsible for the organization of a Panel on Social Cost Value Analysis that will take place in the next HTAi annual meeting. Health Technology Assessment (HTA) should reflect the social norms, preferences, and value judgments of the population. Measuring social preferences for HTA may require a payment vehicle different from the consumers' perspective applied in most stated preference studies. New results of empirical studies designed to assess determinants of social value will be presented, and the far-reaching policy consequences will be discussed.

Vignete – The Value of Freedom: The Dynamics between Capability and Wellbeing
Jasper Ubels will be presenting his work on the capability approach (CA). This is a framework of evaluation which has gained traction in the health economics community. Proponents of the CA argue that the conventional scope of evaluation is too narrow; the scope of evaluation should be the opportunities available to an individual, instead of what the individual has or is. One characteristic of the CA is the importance of freedom and its relation to wellbeing. However, a precise explanation of how freedom and wellbeing are related to each other is currently not available. This study provides an insight in the dynamics between capability freedom and wellbeing.


The DKFZ Division of Health Economics in AES 2019, Albacete Spain (June 2019)
Oral Presentation - Inequalities in cancer incidence among German districts: a spatial analysis exploring the role of behavioral and socioeconomic factors.
The work done by Jana Mader and Karla Hernandez-Villafuerte will be presented in AES 2019. In Germany, regional differences in cancer incidence on state level have been suggested. Internationally, a correlation between socioeconomic status (SES) and cancer incidence at district level has been observed. This generates questions regarding possible variations among districts in the effect of specific health policies. This study adds further support for the correlation of socioeconomic factors, and breast cancer as well as colorectal cancer incidence. Moreover, the analysis brings light on the heterogeneity of the SES effect on cancer incidence by considering cancer type, age and sex.


The DKFZ Division of Health Economics in the European Health Forum (EHFG 2019) in Bad Hofgastein (October 2019)
Panel – Why rare und ultra-rare diseases matter for health policy makers
Prof. Michael Schlander will be part of a discussion on why rare and ultra-rare diseases matter for healthcare decision making. Disease taxonomy specifies groups of morbid conditions sharing common characters that distinguish them from other morbid conditions. The refinement and multiplication of the characters considered to specifying morbid conditions, now recognize more and more pathologies behind a similar clinical presentation, thus improving the precision of medicine. The trend toward precision medicine relies on more accurate patient stratification. It leads to the multiplication of distinguishable diseases entities, and subsequently to the proportional decrease of the prevalence of each individual disease entity, such as common diseases subdivided into increasing numbers of different conditions will progressively join the group of rare diseases and will face similar challenges. This evolution is already sensitive in cancer, where it accompanies the development of new drugs that target molecular defects identified in limited number of patients.

to top